Esomeprazole Treatment of Frequent Heartburn: Two Randomized, Double-Blind, Placebo-Controlled Trials

References

• . Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–1920
   PubMed Web of Science ®Google Scholar
• . Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135(4):1392–1413
   PubMed Web of Science ®Google Scholar
• . Camilleri M, Dubois D, Coulie B, . Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol. 2005;3(6):543–552
   PubMed Web of Science ®Google Scholar
• . Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003;98(7):1487–1493
   PubMed Web of Science ®Google Scholar
• . Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112(5):1448–1456
   PubMed Web of Science ®Google Scholar
• . Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med. 1999;106(6):642–649
   PubMed Web of Science ®Google Scholar
• . Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54(5):710–717
   PubMed Web of Science ®Google Scholar
• . Furu K, Straume B. Use of antacids in a general population: the impact of health-related variables, lifestyle and sociodemographic characteristics. J Clin Epidemiol. 1999;52(6):509–516
   PubMed Web of Science ®Google Scholar
• . Earnest D, Robinson M, Rodriguez-Stanley S, . Managing heartburn at the ‘base’ of the GERD ‘iceberg’: effervescent ranitidine 150 mg b.d. provides faster and better heartburn relief than antacids. Aliment Pharmacol Ther. 2000;14(7):911–918
   PubMed Web of Science ®Google Scholar
• . van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2006;(3):CD002095
   Google Scholar
• . Haag S, Andrews JM, Katelaris PH, . Management of reflux symptoms with over-the-counter proton pump inhibitors: issues and proposed guidelines. Digestion. 2009;80(4):226–234
   PubMed Web of Science ®Google Scholar
• . Nexium [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2012
   Google Scholar
• . Kahrilas PJ, Falk GW, Johnson DA, . Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther. 2000;14(10):1249–1258
   PubMed Web of Science ®Google Scholar
• . Castell DO, Kahrilas PJ, Richter JE, . Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97(3):575–583
   PubMed Web of Science ®Google Scholar
• . Fennerty MB, Johanson JF, Hwang C, Sostek M. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther. 2005;21(4):455–463
   PubMed Web of Science ®Google Scholar
• . Lind T, Rydberg L, Kyleback A, . Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000;14(7):861–867
   PubMed Web of Science ®Google Scholar
• . Wilder-Smith C, Backlund A, Eckerwall G, Lind T, Fjellman M, Röhss K. Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study. Clin Drug Investig. 2008;28(6):333–343
   PubMed Web of Science ®Google Scholar
• . Wilder-Smith C, Lind T, Lundin C, Naucler E, Nilsson-Pieschl C, Rohss K. Acid control with esomeprazole and lansoprazole: a comparative dose-response study. Scand J Gastroenterol. 2007;42(2):157–164
   PubMed Web of Science ®Google Scholar
• . Rohss K, Wilder-Smith C, Naucler E, Jansson L. Esomeprazole 20 mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Investig. 2004;24(1):1–7
   PubMed Web of Science ®Google Scholar
• . Kushner PR, Snoddy AM, Gilderman L, Peura DA. Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies. Postgrad Med. 2009;121(4):67–75
   PubMed Web of Science ®Google Scholar
• . Stull DE, van Hanswijck de Jonge P, Houghton K, Kocun C, Sandor DW. Development of a frequent heartburn index. Qual Life Res. 2011;20(7):1023–1034
   PubMed Web of Science ®Google Scholar
• . Jones R, Crouch SL. Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. Aliment Pharmacol Ther. 1999;13(3):413–419
   PubMed Web of Science ®Google Scholar
• . Lightdale CJ, Schmitt C, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Dig Dis Sci. 2006;51(5):852–857
   PubMed Web of Science ®Google Scholar
• . Allgood LD, Grender JM, Shaw MJ, Peura DA. Comparison of Prilosec OTC (omeprazole magnesium 20.6 mg) to placebo for 14 days in the treatment of frequent heartburn. J Clin Pharm Ther. 2005;30(2):105–112
   PubMed Web of Science ®Google Scholar
• . Bardhan KD, Muller-Lissner S, Bigard MA, . Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. BMJ. 1999;318(7182):502–507
   PubMedGoogle Scholar
• . Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther. 2001;23(7):998–1017
   PubMed Web of Science ®Google Scholar
• . Fendrick AM, Shaw M, Schachtel B, . Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. Clin Gastroenterol Hepatol. 2004;2(1):17–21
   PubMed Web of Science ®Google Scholar
• . Massey S. Esophageal cancer and palliation of dysphagia. Clin J Oncol Nurs. 2011;15(3):327–329
   PubMed Web of Science ®Google Scholar
• . Layke JC, Lopez PP. Esophageal cancer: a review and update. Am Fam Physician. 2006;73(12):2187–2194
   PubMed Web of Science ®Google Scholar
• . Wayman J, Hayes N, Griffin SM. The response of early gastric cancer to proton-pump inhibitors. N Engl J Med. 1998;338(26):1924–1925
   PubMed Web of Science ®Google Scholar
• . Wayman J, Hayes N, Raimes SA, Griffin SM. Prescription of proton pump inhibitors before endoscopy. A potential cause of missed diagnosis of early gastric cancers. Arch Fam Med. 2000;9(4):385–388
   PubMedGoogle Scholar